Estrogen and arteries
Estradiol is one of the most powerful vasodilators in the human body. It promotes nitric oxide release from endothelial cells, improves arterial elasticity, suppresses pro-inflammatory cytokines in vessel walls, and supports HDL production. The dramatic rise in cardiovascular events in women after menopause, from less than half the male rate to surpassing it, tracks closely with estradiol decline.
This is why women's cardiovascular risk profile transforms in their 50s. The protective effect of estradiol disappears, and arterial aging accelerates.
The timing hypothesis
The Manson et al. 13-year follow-up of WHI participants in JAMA 2017 was the turning point. Women in the 50-59 age group who received estrogen-only HRT had:
- Reduced all-cause mortality (risk ratio 0.69)
- Reduced coronary heart disease
- Reduced colorectal cancer
- No increase in breast cancer
Women in the same trial who started after age 70 had increased cardiovascular events, driving the original headlines. The "timing hypothesis" emerged: HRT works with healthy arteries (early menopause) but adds risk to diseased arteries (late menopause). Restoring estrogen to vessels that have already developed atherosclerosis can destabilize plaque; restoring estrogen to healthy vessels prevents the plaque from forming in the first place.
KEEPS and ELITE results
Two follow-up RCTs designed specifically to test the timing hypothesis:
- KEEPS (Kronos Early Estrogen Prevention Study, 2014): newly menopausal women, 4 years HRT vs placebo. No carotid intima-media thickness difference, but improved lipids and reduced subclinical atherosclerosis markers.
- ELITE (2016): women within 6 years of menopause vs more than 10 years out. Carotid IMT progression was significantly slowed in early-treated group; not in late-treated.
The combined message: started near menopause, HRT preserves arterial youth.
Why route of delivery matters
Oral estrogen passes through the liver before reaching circulation. The liver responds by increasing production of clotting factors, inflammatory proteins, and triglycerides. Transdermal estrogen bypasses this entirely.
This explains the divergent VTE (clot) and stroke data: oral oestrogen has measurable VTE risk; transdermal does not. For cardiovascular outcomes specifically, transdermal estradiol is the modern standard of care.
What HRT changes in labs
Typical year-1 changes in cardiovascular markers on transdermal HRT:
| Marker | Direction | Magnitude |
|---|---|---|
| HDL | Up | +5-10% |
| LDL | Down | −5-10% |
| ApoB | Down | −10-15% |
| Triglycerides (transdermal) | Slight down or unchanged | 0 to −10% |
| hs-CRP (transdermal) | Down or unchanged | 0 to −20% |
| Endothelial function (FMD) | Up | +15-25% |
The clinical pearl: The cardiovascular benefit of HRT shows up in subclinical markers (arterial elasticity, lipid profile, inflammation) early. The hard outcome benefits, fewer heart attacks and lower mortality, emerge over 5+ years.
The progesterone factor
The progesterone partner of HRT matters too. Bioidentical micronized progesterone has neutral or slightly favorable cardiovascular effects. Synthetic progestins like medroxyprogesterone partially blunted estrogen's benefits in WHI. Modern protocols default to micronized progesterone, see progesterone for sleep and mood.
Bottom line
The "HRT increases heart attack risk" story is now substantially outdated. For women starting in their 40s or early 50s with transdermal bioidentical estradiol and oral micronized progesterone, the cardiovascular picture is favorable: improved arterial function, better lipids, lower inflammation, and reduced all-cause mortality. The fear that delayed a generation of women from receiving HRT has been a real cost, and the data is finally catching up.